A practical synthesis of a γ-secretase inhibitor

Journal of Organic Chemistry

Volumn 72, Issue 11, 2007, Pages 4149-4155

  Scott, Jeremy P ^a   Lieberman, David R ^a   Beureux, Olivier M ^a   Brands, Karel M J ^a   Davies, Antony J ^a   Gibson, Andrew W ^a   Hammond, Deborah C ^a   McWilliams, Chris J ^b   Stewart, Gavin W ^a   Wilson, Robert D ^a   Dolling, Ulf H ^b  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLONITRILE DERIVATIVES; CYCLOHEXANONE DERIVATIVE; SCALEABLE SYNTHESIS; SECRETASE INHIBITOR;

DERIVATIVES; PARAFFINS; STEREOCHEMISTRY; SUBSTITUTION REACTIONS; SYNTHESIS (CHEMICAL);

ENZYME INHIBITION;

2,5 DIFLUOROPHENYL; 4 CHLOROPHENYLSULFONYL; ACRYLONITRILE; CYCLOHEXANE; CYCLOHEXANONE DERIVATIVE; CYCLOHEXENE DERIVATIVE; GAMMA SECRETASE INHIBITOR; PROPIONIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CATALYST; CONJUGATION; DIELS ALDER REACTION; HYDROGENATION; REACTION ANALYSIS; REDUCTION; STEREOCHEMISTRY; SYNTHESIS;

AMYLOID PRECURSOR PROTEIN SECRETASES; CYCLOHEXENES; ENZYME INHIBITORS; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; STEREOISOMERISM;

EID: 34249779845     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo070407n     Document Type: Article

References (59)

1. (a) Larner, A. Expert Opin. Ther. Pat. 2004, 14, 1403-1420.
2. (b) Citron, M. Nat. Rev. Neurosci. 2004, 5, 677.
3. (c) Parihar, M. S.; Hemnani, T. J. Clin. Neurosci. 2004, 11, 456.
4. (d) Bullock, R. Expert Opin. Investig. Drugs 2004, 13, 303.
5. (e) Esteban, J. A. Trends Neurosci. 2004, 27, 1.
6. (f) Mani, R. B. Statist. Med. 2004, 23, 305.
7. (g) Komilova, A. Y.; Wolfe, M. S. Annu. Rep. Med. Chem. 2003, 38, 41.
8. (h) Aguzzi, A.; Haass, C. Science 2003, 302, 814.
9. (i) Lahiri, D. K.; Farlow, M. R.; Sambamurti, K.; Greig, N. H.; Giacobini, E.; Schneider, L. S. Curr. Drug Targets 2003, 4, 97.
10. (j) Gurwitz, D. Drug Dev. Res. 2002, 56, 45.
11. (k) Walter, J.; Haass, C. Drug Dev. Res. 2002, 56, 201.
12. (l) Wolfe, M. S. Nature Rev. 2002, 859.
13. (m) Selkoe, D. J. J. Clin. Invest. 2002, 110, 1375.
14. (n) Lahiri, D. K.; Farlow, M. R.; Greig, N. H.; Sambamurti, K. Drug Dev. Res. 2002, 56, 267.
15. (a) Churcher, I.; Beher, D.; Best, J. D.; Castro, J. L.; Clarke, E. E.; Gentry, A.; Harrison, T.; Hitzel, L.; Kay, E.; Kerrad, S.; Lewis, H. D.; Morentin-Gutierrez, P.; Mortishire-Smith, R.; Oakley, P. J.; Reilly, M.; Shaw, D. E.; Shearman, M. S.; Teall, M. R.; Williams, S.; Wrigley, J. D. J. Biorg. Med. Chem. Lett. 2006, 16, 280.
16. (b) Churcher, I.; Beher, D. Curr. Pharm. Design 2005, 11, 3363.
17. (c) Harrison, T.; Churcher, I.; Beher, D. Curr. Opin. Drug. Disc Dev. 2004, 7, 709.
18. (d) Brands, K. M. J.; Brewer, S.; Davies, A. J.; Dolling, U. H.; Hammond, D. C.; Lieberman, D. R.; Scott, J. P. WO 2005080309.
19. (e) Brands, K. M. J.; Davies, A. J.; Oakley, P. J.; Scott, J. P.; Shaw, D. E.; Teall, M. R. PCT Int. Appl. WO 2004013090.
20. (f) Churcher, I.; Dinnell, K.; Harrison, T.; Kerrad, S.; Nadin, A. J.; Oakley, P. J.; Shaw, D. E.; Teall, M. R.; Williams, B. J.; Williams, S. PCT Int. Appl. WO 2003018543.
21. (g) Castro Pineiro, J. L.; Churcher, I.; Dinnell, K.; Harrison, T.; Kerrad, S.; Nadin, A. J.; Oakley, P. J.; Owens, A. P.; Shaw, D. E.; Teall, M. R.; Williams, B. J.; Williams, S. PCT Int. Appl. WO 2002081435.
22. Yields reported are of isolated materials corrected for purity as determined by reversed-phase HPLC assay versus authentic standards.
23. (a) Blacklock, T. J.; Butcher, J. W.; Sohar, P.; Lamanec, T. R.; Grabowski, E. J. J. J. Org. Chem. 1989, 54, 3907.
24. (b) Schultz, H. S.; Freyermuth, H. B.; Buc, S. R. J. Org. Chem. 1963, 28, 1140.
25. Sulfone 7 can also be prepared in >90% yield by alkylation of 2,5-difluorobenzylbromide with 4-chlorobenzenesulfinic acid sodium salt in DMF; however, this salt is not commercially available on kilogram scale.
26. 2)l;
27. 3.
28. Scott, J. P.; Hammond, D. C.; Beck, E. M.; Brands, K. M. J.; Davies, A. J.; Dolling, Ulf-H.; Kennedy, D. J. Tetrahedron Lett. 2004, 45, 3345.
29. (a) Gunda, T. E. Synth. Commun. 1992, 22, 2979.
30. (b) DeSolms, S. J. J. Org. Chem. 1976, 41, 2650.
31. (c) For a recent review of the Mannich reaction: Arend, M.; Westermann, B.; Risch, N. Angew. Chem., Int. Ed. 1998, 37, 1044.
32. Crystallographic data for this compound have been deposited at the Cambridge Crystallographic Data Centre. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data-request/cif, by emailing data_ request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033. (a) CCDC 236716.
33. (b) CCDC 236717.
34. (a) Tamura, Y.; Ochiai, H.; Nakamura, T.; Yoshida, Z. Tetrahedron Lett. 1986, 27, 955.
35. (a) Jung, M. E.; McCombs, C. A. Tetrahedron Lett. 1976, 34, 2935.
36. (b) Jung, M. E.; McCombs, C. A. Org. Synth. 1978, 58, 163.
37. (c) Jung, M. E.; McCombs, C. A.; Taked, Y.; Pan, Y-G. J. Am. Chem. Soc. 1981, 103, 6677.
38. Comins, D. L.; Dehghani, A. Tetrahedron Lett. 1992, 33, 6299.
39. Tamura, Y.; Ochiai, H.; Nakamura, T.; Yoshida, Z. Tetrahedron Lett. 1986, 27, 955.
40. Zhang, M.; Azhu, L.; Ma, X.; Dai, M.; Lowe, D. Org. Lett. 2003, 5, 1587.
41. Hydrogenations with catalysts derived from rhodium or iridium did not indicate any reversal in substrate control, yielding 12 as the major product in each case examined.
42. 2(cymene) complexes were prepared according to the literature: Mashima, K.; Kusano, K.; Sate, N.; Matsumura, N.; Nozaki, K.; Kumobayashi, H.; Sayo, N.; Hori, Y.; Ishizaki, T.; Akutagawa, S.; Takaya, H. J. Org. Chem. 1994, 59, 3064.
43. The regiochemistry in the transition states for ruthenium hydride addition to 2 are likely to be identical, but have been assigned arbitrarily pending further mechanistic experimentation.
44. Brown, H. C.; Krishnamurthy, S. J. Am. Chem. Soc. 1972, 94, 7159.
45. (a) For a detailed study and rationalisation of the conformational bias of aryl, arylsulfonyl geminally substituted tertiary carbon centers, see: Scott, J. P.; Mullens, P. R.; Brewer, S. E.; Brands, K. J. M.; Chilenski, J. R.; Davies, A. J.; Gibb, A. D.; Lieberman, D. R.; Oliver, S. F.; Dolling, U-H. Org. Biomol. Chem. 2006, 4, 1806.
46. (b) For the application of this conformational bias in an intramolecular nitrile oxide-olefin cycloaddition, see: Scott, J. P.; Oliver, S. F.; Brands, K. J. M.; Brewer, S. E.; Daves, A. J.; Gibb, A. D.; Hands, D.; Keen, S. P.; Sheen, F. J.; Reamer, R. A.; Wilson, R. D.; Dolling, U. H. J. Org. Chem. 2006, 71, 3086.
47. Wadsworth, W. S.; Emmons, W. D. J. Am. Chem. Soc. 1961, 83, 1733.
48. (a) Diastereoselection was determined by reversed-phase HPLC analysis,
49. 4 reduction of 4 afforded a 67:33 trans/cis mixture from which the trans isomer could be separated chromatographically.
50. 13C NMR studies that indicated the presence of two sets of four quaternary carbon signals and isolated AB proton quartets consistent with methylenes adjacent to the nitrile functions.
51. (a) Martin, S. F.; Gompper, R. J. Org. Chem. 1974, 39, 2814.
52. (b) Kluge, A. F.; Cloudsdale, I. S. J. Org. Chem. 1979, 44, 4847.
53. (c) Magnus, P.; Roy, G. J. Chem. Soc., Chem. Commun. 1979, 822.
54. (d) Broekhof, N. L. J. M.; Jonkers, F. L.; van der Gen, A. Tetrahedron Lett. 1980, 21, 2671.
55. (e) Broekhof, N. L. J. M.; Jonkers, F. L.; van der Gen, A. Tetrahedron Lett. 1979, 20, 2433.
56. (a) Levine, S. G. J. Am. Chem. Soc. 1958, 80, 6150.
57. (b) Anderson, C. L.; Soderquist, J. A.; Kabalka, G. W. Tetrahedron Lett. 1992, 33, 6915.
58. Incomplete conversion of aldehyde 16, likely due to competing enolization, was observed with methoxymethyldiphenyl phosphine oxide under a variety of conditions: Earnshaw, C.; Wallis, C. J.; Warren, S. J. Chem. Soc., Chem. Commun. 1977, 314.
59. Lindgren, B. O.; Nilsson, T. Acta. Chem. Scand. 1973, 27, 888.